文献速递治疗药物监测与药物基因组学抗菌药物管理

阿米卡星用药评估及两款贝叶斯预测软件模型比较

Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing.
PubMed 文献 · Br J Clin Pharmacol · 2020-09-21

本研究评估了成人静脉使用阿米卡星的处方与TDM实践,并比较DoseMeRx®与Abbottbase®两款贝叶斯预测软件中阿米卡星模型的预测性能。结果显示指南依从性欠佳,DoseMeRx®对阿米卡星浓度存在轻微低估,但预测性能可满足指导给药需求。

要点

  • 阿米卡星处方与TDM实践指南依从性欠佳,剂量常低于推荐。
  • DoseMeRx®较实测浓度低估0.9 mg/L(95%CI -1.4至-0.5)。
  • DoseMeRx®峰浓度预测无偏且精确,可满意指导阿米卡星给药。

核心结论

  • 与指南相比,阿米卡星给药和TDM实践欠佳。
  • DoseMeRx®所实施的模型可满意地指导阿米卡星给药。

研究设计与样本

  • 回顾性收集2012-2017年接受静脉阿米卡星成人患者的人口学、病理、给药史、浓度及Abbottbase®预测TDM靶值。
  • 共纳入47例患者的63个阿米卡星疗程。
  • 评估与澳大利亚治疗指南的一致性,并比较DoseMeRx®预测与实测浓度及Abbottbase®预测的TDM靶值。

主要发现

  • 剂量常低于推荐;疗程>48 h时TDM采样时机常与推荐不符,达标率低,34%的剂量调整不适当。
  • DoseMeRx®较实测浓度低估0.9 mg/L(95%CI -1.4至-0.5)。
  • 峰浓度(n=19)预测无偏(-1.7 mg/L,95%CI -5.8至0.8)且精确(8.6%,95%CI 5.4-18.1)。
  • 谷浓度(n=7)预测值最多比实测高1 mg/L。
  • Abbottbase®与DoseMeRx®估算的AUC相似(181 mg h/L 95%CI 161-202 vs 176 mg h/L 95%CI 152-199,P=.59)。

临床怎么用

  • 可考虑使用DoseMeRx®贝叶斯预测软件辅助阿米卡星TDM及剂量调整。
  • 应关注阿米卡星剂量不足及TDM采样时机不恰当的问题,提高指南依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Bayesian forecasting software can assist in guiding therapeutic drug monitoring (TDM)-based dose adjustments for amikacin to achieve therapeutic targets. This study aimed to evaluate amikacin prescribing and TDM practices, and to determine the suitability of the amikacin model incorporated into the DoseMeRx® software as a replacement for the previously available software (Abbottbase®). METHODS: Patient demographics, pathology, amikacin dosing history, amikacin concentrations and Abbottbase® predicted TDM targets (area under the curve up to 24 hours, maximum concentration and trough concentration) were collected for adults receiving intravenous amikacin (2012-2017). Concordance with the Australian Therapeutic Guidelines was assessed. Observed and predicted amikacin concentrations were compared to determine the predictive performance (bias and precision) of DoseMeRx®. Amikacin TDM targets were predicted by DoseMeRx® and compared to those predicted by Abbottbase®. RESULTS: Overall, guideline compliance for 63 courses of amikacin in 47 patients was suboptimal. Doses were often lower than recommended. For therapy >48 h, TDM sample collection timing was commonly discordant with recommendations, therapeutic target attainment low and 34% of dose adjustments inappropriate. DoseMeRx® under-predicted amikacin concentrations by 0.9 mg/L (95% confidence interval [CI] -1.4 to -0.5) compared with observed concentrations. However, maximum concentration values (n = 19) were unbiased (-1.7 mg/L 95%CI -5.8 to 0.8) and precise (8.6% 95%CI 5.4-18.1). Predicted trough concentration values (n = 7) were, at most, 1 mg/L higher than observed. Amikacin area under the curve values estimated using Abbottbase® (181 mg h/L 95%CI 161-202) and DoseMeRx® (176 mg h/L 95%CI 152-199) were similar (P = .59). CONCLUSION: Amikacin dosing and TDM practice was suboptimal compared with guidelines. The model implemented by DoseMeRx® is satisfactory to guide amikacin dosing.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ryan AC, Carland JE, McLeay RC, et al. Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing. Br J Clin Pharmacol. 2020. PMID: 32881037. doi:10.1111/bcp.14542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。